Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Study Information
Alliance Study ID: AFT-16
NCT Study ID (ClinicalTrials.gov): NCT03102242
Alliance Committee: Respiratory Cancer
Disease or Cancer Type: Lung Cancer & Mesothelioma
Alliance Study Chair: Helen Ross, MD
Status: COMPLETED
Study Description
Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information